Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alliance for Detection of Colon Cancer

By Labmedica staff writers
Posted on 01 Aug 2002
A long-term strategic partnership has been announced to commercialize a DNA test for the early detection of colorectal cancer in the average-risk population. More...


Under their agreement, Laboratory Corporation of America Holdings (Burlington, NC, USA) will pay the developer of the test, Exact Sciences Corp. (Maynard, MA, USA), royalty fees and up to US$75 million in various payments for a five-year exclusive license, followed by a nonexclusive license for the life of the patents. Exact Sciences says there is no other DNA test currently available for the early detection of colorectal cancer in an average-risk population.

Called PreGen-Plus, the test works by isolating human DNA, shed in the colon every day and carried out of the body in stool, and by analyzing that DNA for mutations associated with colorectal cancer. PreGen-Plus is noninvasive and requires no dietary modification or bowel preparation. The process involves collecting a single stool sample and shipping the sample in a supplied container to a laboratory for analysis.

"We believe PreGen-Plus could be the most important molecular test identified to date for the millions of Americans who are candidates for colorectal cancer screening annually,” said Thomas P. MacMahon, chairman and CEO of LabCorp.




Related Links:
LabCorp
Exact Sciences

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.